<a href="https://laohu8.com/S/EPIX">ESSA Pharma Inc.</a> Publishes Shareholder Letter for Fiscal Year 2025
ESSA Pharma Inc. has issued a letter to shareholders regarding a Business Combination Agreement entered into on July 13, 2025. The agreement involves a transaction where XenoTherapeutics, Inc., through its subsidiary Xeno Acquisition Corp., will acquire all issued and outstanding common shares of ESSA Pharma Inc. The company plans to reduce the capital of its common shares and make a concurrent distribution, subject to approval from the Supreme Court of British Columbia. The letter provides information on the potential tax treatment of the proposed distribution and highlights considerations relevant to shareholders' individual circumstances. More detailed tax information will be available in the proxy statement and management information circular filed with the United States Securities and Exchange Commission. The full letter can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-072771), on July 31, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。